Brain Cancer Treatment Regimens
View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
Researchers sought to determine the rates of VTE and major bleeding in patients with glioblastoma.
For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.
A large retrospective analysis demonstrated that a delay of 4 to 8 weeks for adjuvant radiotherapy following surgical resection of glioblastoma improved survival.
A glycoprotein in Ebola called the mucin-like domain may be of interest in the development of an oncolytic for brain cancer.
Maximal resection of contrast-enhanced tumor linked to increased overall survival across all subgroups.
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors.
This study involved the engineering of CAR-T cells specific for the EGFRvIII antigen to also secrete bispecific T cell engagers (BiTEs) against wild-type EGFR.
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
Lomustine plus bevacizumab may increase progression-free, but not overall, survival versus lomustine alone in progressive glioblastoma.